Search Results

You are looking at 51 - 56 of 56 items for :

  • "myeloid growth factors" x
Clear All
Full access

Katy Winckworth-Prejsnar, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C. Lyn Fitzgerald and Robert W. Carlson

given disease setting. 30 , 31 Dr. Crawford, chair of the NCCN Myeloid Growth Factors Panel, discussed NCCN category of evidence designation without clinical trial data for all indications of filgrastim-sndz. Within the NCCN Guidelines, although

Full access

Stephen Harnicar

should be suspended and then reinitiated at a reduced dose of 300 mg. Data support the use of myeloid growth factors for patients with resistant neutropenia. 28 Grade 3 to 4 thrombocytopenia is managed similarly; therapy should be held until the platelet

Full access

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

saturation, vitamin B 12 , and folate and correction of nutritional deficiencies if present is recommended for patients with grade 3/4 anemia. Red blood cell transfusions are indicated in symptomatic patients. Myeloid growth factor support can be used in

Full access

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman and Hema Sundar

include appropriate growth factor support (see the NCCN Guidelines for Myeloid Growth Factors for growth factor support; to view the most recent version of these guidelines, visit NCCN.org ). A list of specific chemotherapy regimens is available in “Bone

Full access

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin and Charles C. Williams Jr.

recommended therapy for patients with limited-stage disease (category 1). 49 , 50 , 58 In combination with thoracic radiotherapy, EP causes an increased risk of esophagitis, pulmonary toxicity, and hematologic toxicity. 59 The use of myeloid growth factors

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

The EORTC issued similar recommendations for the prophylactic use of G-CSF in older patients with cancer. 218 The NCCN Guidelines for Myeloid Growth Factors address the use of G-CSFs in patients with solid tumors and nonmyeloid malignancies (to view